January/February 2022 • PharmaTimes Magazine • 37-38
// APPOINTMENTS //
Appointments
Mover of the Month
Vanessa Broadhurst has been appointed as Johnson & Johnson’s executive vice president of global corporate affairs, expanding the company’s senior management team. She previously served the company as group chairman of global commercial strategy organisation, leading a team that focused on Janssen’s commercialisation and launch strategies. Broadhurst brings to her new role extensive leadership experience from her earlier work as a member of the Janssen Americas Leadership Team. Prior to her position as company group chairman, Broadhurst demonstrated successful leadership while working with a variety of multibillion-dollar US organisations at Janssen, including accounts specialising in infectious diseases, internal medicine, cadiovascular health and metabolism.
STADA has appointed Erin Federman as its new global commercial head for biosimilars, overseeing the commercialisation of STADA’s biosimilars pipeline and portfolio. Federman brings a wealth of knowledge to the role, previously managing partnerships in biosimilar developments and European biosimilar commercial operations for Mylan/Viatris, while gaining valuable experience leading global marketing for Novo Nordik’s insulin portfolio.
Amarin has appointed Chris Hewitt as medical director for the UK and Ireland, expanding its established senior management team. In his new position, Hewitt is responsible for medical oversight for the UK affiliate including medical affairs, medical information and compliance, with an emphasis on scientific communications and medical education. He leads the UK medical team and sits on Amarin’s EU Medical Leadership Team. Prior to his new role, Hewitt worked as a senior global medical affairs leader for AstraZeneca in the cardiovascular, renal and metabolic portfolio and, as a UK-trained physician, he also previously worked at the NHS, specialising in adult medicine and oncology.
BioMarin has appointed former CEO of Celgene Corporation Mark Alles to its Board of Directors. Alles brings a wealth of knowledge from his role as a leader in the biopharmaceutical industry with extensive experience in handling financial and commercial affairs. Previous to his work as CEO, Alles served as chief executive officer of Celgene Corporation from 2016.
Terns Pharmaceuticals welcomes Diana Chung as its new senior vice president and chief development officer. Chung brings a vast amount of scientific and clinical expertise, having previously served at Terns Pharmaceuticals as senior vice president of clinical development and operations. She has more than 20 years of experience in the industry, specifically in drug discovery and clinical development.
James Swanson has been appointed as Johnson & Johnson’s new executive vice president and chief of information officer. Swanson has previously worked at Bayer Crop Science where he served as part of the executive leadership team as chief information officer and head of digital transformation. Swanson’s new role promises to bolster the expansion of J&J’s executive management team.
The National Institute for Health and Care Excellence (NICE) has appointed Samantha Roberts as its new chief executive officer. The announcement comes after Gillian Leng decided to step down from her position of CEO for NICE after 20 months, for personal reasons. Roberts currently serves as managing director for health and care at Legal and General insurance group. She brings extensive experience to the role, having spent four years working at NHS England as director of innovation, research and life sciences. Roberts then served as chief executive of the Accelerated Access Collaborative. She begins her new role on 1 February 2022.
Context Therapeutics has appointed Christopher Beck as its new senior vice president of operations. Beck has joined Context after serving as vice president of programme management at Galera Therapeutics. Prior to his work at Galera, he spent nearly a decade at Shire where he helped in creating the company’s first global project management and resource capacity planning capability.
Axcella Therapeutics has appointed Margaret Koziel as its chief medical officer, leading clinical development and regulatory affairs. Dr Koziel served as the Axcella’s vice president for clinical development. With nearly 90 papers published in journals that include the New England Journal of Medicine, Koziel brings a wealth of biopharma and academic knowledge to the organisation.
Johnson & Johnson has appointed Bill Hait as executive vice president, chief of external innovation and as a medical safety and global public health officer. Hait brings a wealth of experience, having worked for the company since 2007, extensively building on the company’s external R&D pipeline, creating new solutions that use J&J’s pharmaceutical and medical devices.
Johnson & Johnson has appointed Mathai Mammen as its new executive vice president of pharmaceuticals and R&D. Having served as global head of R&D at the Janssen, part of Johnson & Johnson, Mammen’s work has been recognised as key in focusing company research efforts and supporting development teams globally in the pursuit of scientific and technological breakthroughs.